Display options
Cite
Redeker A, Remmerswaal EBM, van der Gracht ETI, et al. The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. Front Immunol. 2018;8:1953doi: 10.3389/fimmu.2017.01953.
Redeker, A., Remmerswaal, E. B. M., van der Gracht, E. T. I., Welten, S. P. M., Höllt, T., Koning, F., Cicin-Sain, L., Nikolich-Žugich, J., Ten Berge, I. J. M., van Lier, R. A. W., van Unen, V., & Arens, R. (2017). The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. Frontiers in immunology, 81953. https://doi.org/10.3389/fimmu.2017.01953
Redeker, Anke, et al. "The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose." Frontiers in immunology vol. 8 (2017): 1953. doi: https://doi.org/10.3389/fimmu.2017.01953
Redeker A, Remmerswaal EBM, van der Gracht ETI, Welten SPM, Höllt T, Koning F, Cicin-Sain L, Nikolich-Žugich J, Ten Berge IJM, van Lier RAW, van Unen V, Arens R. The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose. Front Immunol. 2018 Jan 10;8:1953. doi: 10.3389/fimmu.2017.01953. eCollection 2017. PMID: 29367854; PMCID: PMC5768196.
Copy Download .nbib Format: NLM
Share it on

Front Immunol. 2018 Jan 10;8:1953. doi: 10.3389/fimmu.2017.01953. eCollection 2017.

The Contribution of Cytomegalovirus Infection to Immune Senescence Is Set by the Infectious Dose.

Frontiers in immunology

Anke Redeker, Ester B M Remmerswaal, Esmé T I van der Gracht, Suzanne P M Welten, Thomas Höllt, Frits Koning, Luka Cicin-Sain, Janko Nikolich-Žugich, Ineke J M Ten Berge, René A W van Lier, Vincent van Unen, Ramon Arens

Affiliations

  1. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands.
  2. Department of Experimental Immunology, Academic Medical Center, Amsterdam, Netherlands.
  3. Renal Transplant Unit, Division of Internal Medicine, Academic Medical Center, Amsterdam, Netherlands.
  4. Delft University of Technology, Delft, Netherlands.
  5. Helmholtz Centre for Infection Research, Braunschweig, Germany.
  6. Department of Immunobiology, University of Arizona College of Medicine, Tucson, AZ, United States.
  7. Sanquin Blood Supply Foundation and Landsteiner Laboratory, Amsterdam, Netherlands.

PMID: 29367854 PMCID: PMC5768196 DOI: 10.3389/fimmu.2017.01953

Abstract

The relationship between human cytomegalovirus (HCMV) infections and accelerated immune senescence is controversial. Whereas some studies reported a CMV-associated impaired capacity to control heterologous infections at old age, other studies could not confirm this. We hypothesized that these discrepancies might relate to the variability in the infectious dose of CMV occurring in real life. Here, we investigated the influence of persistent CMV infection on immune perturbations and specifically addressed the role of the infectious dose on the contribution of CMV to accelerated immune senescence. We show in experimental mouse models that the degree of mouse CMV (MCMV)-specific memory CD8

Keywords: CMV; immunesenesence; memory CD8 T cells; memory inflation; mouse models

References

  1. Pediatr Infect Dis J. 2010 Dec;29(12):1105-10 - PubMed
  2. PLoS Pathog. 2012;8(8):e1002850 - PubMed
  3. J Virol. 2016 Apr 14;90(9):4402-11 - PubMed
  4. PLoS Pathog. 2016 Dec 15;12 (12 ):e1006072 - PubMed
  5. PLoS Pathog. 2012;8(8):e1002849 - PubMed
  6. J Gerontol A Biol Sci Med Sci. 2017 Sep 1;72 (9):1163-1170 - PubMed
  7. J Immunol. 2003 Feb 15;170(4):2022-9 - PubMed
  8. J Virol. 2006 Nov;80(21):10436-56 - PubMed
  9. Exp Gerontol. 2014 Jul;55:54-62 - PubMed
  10. J Virol. 2015 May;89(9):5110-23 - PubMed
  11. J Exp Med. 1987 Sep 1;166(3):668-77 - PubMed
  12. Vaccine. 2011 Jun 24;29(29-30):4869-74 - PubMed
  13. J Immunol. 2008 May 15;180(10):6472-6 - PubMed
  14. Infect Dis (Lond). 2016;48(6):436-42 - PubMed
  15. J Infect Dis. 2010 Feb 1;201(3):386-9 - PubMed
  16. J Exp Med. 2005 Sep 5;202(5):673-85 - PubMed
  17. J Immunol. 2011 Apr 1;186(7):3874-81 - PubMed
  18. Vaccine. 2013 Jan 11;31(4):685-90 - PubMed
  19. Immun Ageing. 2016 Jan 05;13:1 - PubMed
  20. Sci Transl Med. 2015 Apr 1;7(281):281ra43 - PubMed
  21. Viral Immunol. 2009 Feb;22(1):67-72 - PubMed
  22. Exp Gerontol. 2002 Jan-Mar;37(2-3):445-53 - PubMed
  23. Nat Rev Immunol. 2016 Jun;16(6):367-77 - PubMed
  24. Vaccine. 2003 Sep 8;21(25-26):3826-36 - PubMed
  25. J Immunol. 2007 Sep 15;179(6):4283-91 - PubMed
  26. J Med Virol. 1997 Jun;52(2):200-5 - PubMed
  27. Eur J Immunol. 2015 Apr;45(4):954-7 - PubMed
  28. IEEE Trans Vis Comput Graph. 2017 Jul;23 (7):1739-1752 - PubMed
  29. BMJ Open Diabetes Res Care. 2015 Oct 13;3(1):e000140 - PubMed
  30. Trends Immunol. 2012 Feb;33(2):84-90 - PubMed
  31. Age (Dordr). 2014 Feb;36(1):287-97 - PubMed
  32. Nature. 2007 May 17;447(7142):326-9 - PubMed
  33. Eur J Immunol. 2014 Apr;44(4):1046-57 - PubMed
  34. Mech Ageing Dev. 2000 Dec 20;121(1-3):187-201 - PubMed
  35. J Exp Med. 1994 Jan 1;179(1):185-93 - PubMed
  36. Aging Cell. 2016 Feb;15(1):14-21 - PubMed
  37. J Infect Dis. 2014 May 15;209(10):1635-41 - PubMed
  38. Age (Dordr). 2013 Jun;35(3):985-91 - PubMed
  39. Microbes Infect. 2003 Nov;5(13):1263-77 - PubMed
  40. Vaccine. 2015 Mar 17;33(12):1433-9 - PubMed
  41. Exp Gerontol. 2016 May;77:87-95 - PubMed
  42. J Immunol. 2014 Sep 15;193(6):2622-9 - PubMed
  43. J Virol Methods. 1991 Jun;33(1-2):191-8 - PubMed
  44. J Clin Microbiol. 1999 May;37(5):1489-97 - PubMed
  45. J Virol. 2013 Apr;87(8):4486-95 - PubMed
  46. J Med Virol. 2013 Sep;85(9):1557-60 - PubMed
  47. Rev Med Virol. 2010 Jul;20(4):202-13 - PubMed
  48. J Immunol. 2012 Dec 1;189(11):5356-66 - PubMed
  49. J Gerontol A Biol Sci Med Sci. 2015 Oct;70(10 ):1210-8 - PubMed

Publication Types

Grant support